Plasma metabolomic profiles in different stages of CKD.

BACKGROUND AND OBJECTIVES CKD is a common public health problem. Identifying biomarkers adds prognostic/diagnostic value by contributing to an understanding of CKD at the molecular level and possibly defining new drug targets. Metabolomics provides a snapshot of biochemical events at a particular time in the progression of CKD. This cross-sectional metabolomics study ascertained whether plasma metabolite profiles are significantly different in CKD stages 2, 3, and 4. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS An analysis of plasma metabolites, using gas and liquid chromatography coupled to mass spectrometry, was conducted on 30 nondiabetic men ages 40-52 years, with 10 participants each in CKD stages 2, 3, and 4 based on their estimated GFR (calculated by the Modified Diet in Renal Disease formula). Participants were recruited in late 2008, and plasma samples were tested at Metabolon Inc and analyzed in 2012. RESULTS Comparison of stage 3/stage 2 identified 62 metabolites that differed (P ≤ 0.05), with 39 higher and 23 lower in stage 3 compared with stage 2; comparisons of stage 4/stage 2 identified 111 metabolites, with 66 higher and 45 lower; and comparisons of stage 4/stage 3 identified 11 metabolites, with 7 higher and 4 lower. Major differences in metabolite profiles with increasing stage of CKD were observed, including altered arginine metabolism, elevated coagulation/inflammation, impaired carboxylate anion transport, and decreased adrenal steroid hormone production. CONCLUSIONS Global metabolite profiling of plasma uncovered potential biomarkers of stages of CKD. Moreover, these biomarkers provide insight into possible pathophysiologic processes that may contribute to progression of CKD.

[1]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  T A Louis,et al.  Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. , 2001, Journal of the American Society of Nephrology : JASN.

[3]  S. Mocanda THE L-ARGININE-NITRIC OXIDE PATHWAY , 1992 .

[4]  M. Otagiri,et al.  A uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropionate induces cell damage to proximal tubular cells via the generation of a radical intermediate. , 2012, Biochemical pharmacology.

[5]  Kdoqi Disclaimer K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  M. Kimoto,et al.  Detection of NG,NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. , 1995, Journal of biochemistry.

[7]  孝彦 小野 慢性腎臓病(CKD)における凝固系と凝固第Xa因子の役割 , 2012 .

[8]  P. López-Jaramillo,et al.  The L-arginine: nitric oxide pathway. , 1993, Current opinion in nephrology and hypertension.

[9]  M. Chonchol,et al.  Disorders of hemostasis associated with chronic kidney disease. , 2010, Seminars in thrombosis and hemostasis.

[10]  C. Wilcox Asymmetric Dimethylarginine and Reactive Oxygen Species: Unwelcome Twin Visitors to the Cardiovascular and Kidney Disease Tables , 2012, Hypertension.

[11]  V. V. van Hinsbergh,et al.  Endothelium—role in regulation of coagulation and inflammation , 2011, Seminars in Immunopathology.

[12]  Corey D. DeHaven,et al.  Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. , 2009, Analytical chemistry.

[13]  Charles E. McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[14]  E. Schwedhelm,et al.  The role of asymmetric and symmetric dimethylarginines in renal disease , 2011, Nature Reviews Nephrology.

[15]  Jiang He,et al.  Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. , 2002, Journal of the American Society of Nephrology : JASN.

[16]  Y. Kakimoto,et al.  Isolation and Identification of Ng,Ng- and Ng,N'g-Dimethylarginine, Nε-Mono-, Di-, and Trimethyllysine, and Glucosylgalactosyl- and Galactosyl-δ-hydroxylysine from Human Urine , 1970 .

[17]  A. Zanchetti,et al.  Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. , 2001, Journal of the American Society of Nephrology : JASN.

[18]  K. Zacharowski,et al.  Novel Aspects of Fibrin(ogen) Fragments during Inflammation , 2011, Molecular medicine.

[19]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  H. W. Lee,et al.  Purification and characterization of protein methylase I (S-adenosylmethionine: protein-arginine methyltransferase; EC 2.1.1.23) from calf brain. , 1978, Methods in cell biology.

[21]  E. Rhee,et al.  New insights into uremia-induced alterations in metabolic pathways , 2011, Current opinion in nephrology and hypertension.

[22]  R. Hebbel,et al.  Endothelial nitric oxide synthase and nitric oxide regulate endothelial tissue factor expression in vivo in the sickle transgenic mouse , 2009, American journal of hematology.

[23]  P. Vallance,et al.  Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. , 1997, Kidney international.

[24]  R. Vanholder,et al.  PROGRESS IN UREMIC TOXIN RESEARCH: Protein‐Bound Toxins—Update 2009 , 2009, Seminars in dialysis.

[25]  T. Niwa,et al.  Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production , 2012, Analytical and Bioanalytical Chemistry.

[26]  M. Pfeffer,et al.  Cardiovascular risk in chronic kidney disease. , 2004, Kidney international. Supplement.

[27]  A. Collins,et al.  Projecting the number of patients with end-stage renal disease in the United States to the year 2015. , 2005, Journal of the American Society of Nephrology : JASN.

[28]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[29]  C. Stehouwer,et al.  Mild-to-moderate renal impairment is associated with platelet activation: a cross-sectional study. , 2008, Clinical nephrology.

[30]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Anne M. Evans,et al.  Organization of GC/MS and LC/MS metabolomics data into chemical libraries , 2010, J. Cheminformatics.

[32]  Ian G. Charles,et al.  Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. , 1999, The Biochemical journal.

[33]  Lining Guo,et al.  Untargeted Metabolomic Profiling as an Evaluative Tool of Fenofibrate-Induced Toxicology in Fischer 344 Male Rats , 2009, Toxicologic pathology.

[34]  K. Williams,et al.  Structural specificity of substrate for S-adenosylmethionine:protein arginine N-methyltransferases. , 1995, Biochimica et biophysica acta.

[35]  E. Mishima,et al.  Metabolomic profiling of uremic solutes in CKD patients , 2010, Hypertension Research.

[36]  M. Kimoto,et al.  Detection of NG,NGDimethylarginine Dimethylaminohydrolase in Human Tissues Using a Monoclonal Antibody , 1995 .

[37]  D. Portilla,et al.  Metabolomics as an extension of proteomic analysis: study of acute kidney injury. , 2007, Seminars in nephrology.

[38]  S. Moncada,et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.

[39]  M. Domanski,et al.  The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. , 2000, Journal of the American College of Cardiology.

[40]  E. Closs,et al.  Plasma membrane transporters for arginine. , 2004, The Journal of nutrition.

[41]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  S. Moncada,et al.  The L-arginine-nitric oxide pathway. , 1993, The New England journal of medicine.

[43]  Adele Cutler,et al.  An application of Random Forests to a genome-wide association dataset: Methodological considerations & new findings , 2010, BMC Genetics.